comparemela.com

Philipa Serlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER .

United statesIsrael generalPhilip serlinTwitterand linkedinPhilipa serlinGloria biosciencesMoran meirJohn laceyGloria bioscienceExchange commission onMedicaid servicesLifesci advisorsWashington university in stInternational society for pharmacoeconomicsOutcomes research onAmerican society of clinical oncology

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER .

United statesIsrael generalNew yorkGeorgia world congress centerJohn laceyTwitterand linkedinMoran meirJeffreyr skaarPhilipa serlinLifesci advisorsInternational society for pharmacoeconomicsOutcomes researchExchange commission onSecurities exchangeValue in healthSociety for health economics

BioLineRx : Form 20-F/A (Amendment No 1 -March 28, 2024 at 05:36 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A .

United statesIsrael generalPhilipa serlinSecurities exchangeBiolinerx ltdInternational financial reporting standardsCompany contact personExchange commissionInternational accounting standards boardPricewaterhousecoopers internationalCompanies lawCompany american depositaryIsrael companies lawMark oneSecurities exchange actMa ayan street modi in

BioLineRx : Report of Periodic or Interim Report -March 26, 2024 at 08:26 am EDT

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE.

District of columbiaUnited statesIsrael generalGloria biosciencesMoran meirPhilipa serlinPhilip serlinStates john laceyColumbia universityNational comprehensive cancer networkExchange commissionWashington universityExchange commission onBiolinerx ltdSecurities exchangeAmerican society of hematology

BioLineRx : Annual Report on Form 20-F FOR 2023 -March 26, 2024 at 08:40 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F .

United statesIsrael generalPhilipa serlinCompany american depositaryBiolinerx ltdIsrael companies lawInternational accounting standards boardInternational financial reporting standardsCompany contact personSecurities exchangeExchange commissionCompanies lawMark oneSecurities exchange actMa ayan street modi inDepositary shares

vimarsana © 2020. All Rights Reserved.